Research Publications

2019

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

06 Jun 2019

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nature Medicine. 2019.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

04 Jun 2019

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New England Journal of Medicine.2019.

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

03 Jun 2019

Long G, Saw R, Lo S, Nieweg O, Shannon K, Gonzalez M et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. The Lancet Oncology. 2019.

Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation

01 Jun 2019

van Baar M, Guminski A, Ferguson P, Martin L. Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Reports. 2019;5(6):491-494.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

31 May 2019

Rozeman E, Menzies A, van Akkooi A, Adhikari C, Bierman C, van de Wiel B et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. The Lancet Oncology. 2019.

LNK suppresses interferon signaling in melanoma

20 May 2019

Ding L, Sun Q, Edwards J, Fernández L, Ran X, Zhou S et al. LNK suppresses interferon signaling in melanoma. Nature Communications. 2019;10(1).

Estimated risk of progression of lentigo maligna to lentigo maligna melanoma.

14 May 2019

Menzies S, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S et al. Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Research. 2019;1.

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

12 Apr 2019

Mittal D, Lepletier A, Madore J, Aguilera A, Stannard K, Blake S et al. CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunology Research. 2019;7(4):559-571.

Reflectance Confocal Microscopy made easy: the four must-know key features for the diagnosis of melanoma and non-melanoma skin cancers

04 Apr 2019

Pellacani G, Scope A, Gonzalez S, Guitera P, Farnetani F, Malvehy J et al. Reflectance Confocal Microscopy made easy: the four must-know key features for the diagnosis of melanoma and non-melanoma skin cancers. Journal of the American Academy of Dermatology. 2019.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma

28 Mar 2019

Jansen Y, Rozeman E, Mason R, Goldinger S, Geukes Foppen M, Hoejbergs L et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology. 2019.

Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials.

26 Mar 2019

Edwards J, Tasker A, Silva I, Quek C, Batten M, Ferguson A et al. Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naïve melanoma: implications for clinical trials. Clinical Cancer Research. 2019.

False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.

25 Mar 2019

Nijhuis A, Dieng M, Khanna N, Lord S, Dalton J, Menzies A et al. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. Annals of Surgical Oncology. 2019.

Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients

23 Mar 2019

Nijhuis A, de A.O. Santos Filho I, Uren R, Thompson J, Nieweg O. Clinical importance and surgical management of sentinel lymph nodes in the popliteal fossa of melanoma patients. European Journal of Surgical Oncology. 2019.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

21 Mar 2019

Heinzerling L, Ascierto P, Dummer R, Gogas H, Grob J, Lebbe C et al. Adverse events 2.0—Let us get SERIOs. European Journal of Cancer. 2019;112:29-31.

Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.

18 Mar 2019

Hong A, Ferguson P, Dodds T, Jones D, Li M, Yang J et al. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer. Oral Oncology. 2019;92:33-39.

Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system.

15 Mar 2019

Haydu L, Thompson J, Scolyer R, Gershenwald, J. Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. European Journal of Cancer. 2019;112:9-11.

Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers.

13 Mar 2019

Dessinioti C, Dimou N, Geller A, Stergiopoulou A, Lo S, Keim U et al. Distinct clinicopathological and prognostic features of thin nodular primary melanomas: an international study from 17 centers. JNCI: Journal of the National Cancer Institute. 2019.

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.

12 Mar 2019

Lee J, Saw R, Thompson J, Lo S, Spillane A, Shannon K et al. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology. 2019.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

27 Feb 2019

Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. Journal of Clinical Oncology. 2019;37(11):867-875.

Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.

15 Feb 2019

Pires da Silva I, Glitza I, Haydu L, Johnpulle R, Banks P, Grass G et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research. 2019.

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

11 Feb 2019

Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J et al. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell. 2019.

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas

29 Jan 2019

Quek C, Rawson R, Ferguson P, Shang P, Silva I, Saw R et al. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget. 2019;10(9).

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.

19 Jan 2019

Kim H, Duong J, Gonzalez M, Long G, Menzies A, Rizos H et al. Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. Cancer Chemotherapy and Pharmacology. 2019.